Arcturus Therapeutics Holdings Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph E. Payne
- Full Time Employees
- 109
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10628 Science Center Drive San Diego CA United States of America 92121
- IPO Date
- May 22, 2013
- CIK
- 0001768224
- Website
- arcturusrx.com
- Similar Companies
- Business
- Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) develops and commercializes messenger RNA (mRNA) medicines and vaccines targeting infectious diseases and rare disorders in the liver and respiratory system; its core offerings include self-amplifying mRNA (sa-mRNA) vaccine platforms such as KOSTAIVE, the first approved sa-mRNA COVID-19 vaccine, partnered programs for SARS-CoV-2 and influenza vaccines with CSL Seqirus, and therapeutic candidates like ARCT-810 for ornithine transcarbamylase (OTC) deficiency and ARCT-032 (LunairCF) for cystic fibrosis, leveraging proprietary enabling technologies comprising LUNAR lipid-mediated delivery systems, STARR mRNA technology, and in-house mRNA drug substance and drug product manufacturing. The company's versatile RNA platforms support multiple nucleic acid modalities, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics, protected by an extensive patent portfolio exceeding 500 patents and applications across the U.S., Europe, Japan, China, and other jurisdictions. Founded in 2013 and headquartered in San Diego, California, Arcturus operates globally with significant research, development, manufacturing, and clinical activities in the U.S. and Asia, including a joint venture in Japan called ARCALIS for mRNA vaccine and therapeutic production; it maintains a multicultural team serving patients worldwide through subsidiaries focused on late-stage RNA therapeutics and vaccines. Recent developments encompass the European Commission's approval of KOSTAIVE in February 2025, positive interim Phase 2 data for ARCT-810 in June 2025 demonstrating proof-of-concept in OTC deficiency, interim Phase 2 results for the cystic fibrosis program in October 2025, a strategic prioritization of core mRNA therapeutics for CF and OTC with cost reductions extending cash runway into early 2028 as announced in first-quarter 2025 updates, U.S. FDA Fast Track designation for pandemic influenza candidate ARCT-2304 in April 2025, expansion of San Diego operations, and the appointment of Moncef Slaoui as Chair Designate in February 2025.
Company News
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
56,895 Shares in Arcturus Therapeutics Holdings Inc. $ARCT Bought by Hsbc Holdings PLC
BlackRock Inc. Invests $17.57 Million in Arcturus Therapeutics Holdings Inc. $ARCT
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates
Arcturus Therapeutics Q2 Earnings Call Highlights
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
Financial Review: Arcturus Therapeutics (NASDAQ:ARCT) vs. Zenas BioPharma (NASDAQ:ZBIO)
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $24.25 Consensus Target Price from Analysts
Amova Asset Management Americas Inc. Grows Stock Holdings in Arcturus Therapeutics Holdings Inc. $ARCT